Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer
暂无分享,去创建一个
L. Wilson | R. Decker | James B. Yu | Henry S. Park | C. Rutter | C. Corso | A. Kim | E. Wang
[1] D. Winchester,et al. Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States , 2017, Annals of Surgical Oncology.
[2] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[3] Quynh-Thu Le,et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Renato Martins,et al. Non-small cell lung cancer, version 1.2015. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] J. Sosa,et al. Increased hospital volume is associated with improved outcomes following abdominal-based breast reconstruction , 2014, Journal of plastic surgery and hand surgery.
[6] C. Stevens,et al. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. , 2014, International journal of radiation oncology, biology, physics.
[7] Damon C Scales,et al. Association between arterial catheter use and hospital mortality in intensive care units. , 2014, JAMA internal medicine.
[8] S. Hung,et al. Higher caseload improves cervical cancer survival in patients treated with brachytherapy , 2014, Radiation oncology.
[9] Tae Hyun Kim,et al. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. , 2014, International journal of radiation oncology, biology, physics.
[10] Tae Hyun Kim,et al. Poster Viewing AbstractIs Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer Beneficial?: A Multi-institutional Propensity-Score Matched Analysis , 2014 .
[11] R. Weichselbaum,et al. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. , 2014, Clinical lung cancer.
[12] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[13] D. Sher,et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non‐small cell lung cancer in the National Cancer Data Base , 2014, Cancer.
[14] N. Sharma,et al. Controversies in the management of stage III non-small-cell lung cancer , 2014, Expert review of anticancer therapy.
[15] C. Faivre-Finn,et al. How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? , 2014, Lung cancer.
[16] B. Monk,et al. Impact of facility volume on therapy and survival for locally advanced cervical cancer. , 2014, Gynecologic oncology.
[17] M. Krasnik,et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Koning,et al. Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: a systematic review of the literature. , 2013, Clinical lung cancer.
[19] J. Sonke,et al. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] Adam Dicker,et al. Radiotherapy protocol deviations and clinical outcomes: A meta-analysis of cooperative group clinical trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Boffa,et al. Impact of hospital volume of thoracoscopic lobectomy on primary lung cancer outcomes. , 2012, The Annals of thoracic surgery.
[22] D. Schrag,et al. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Amy Y. Chen,et al. Improved survival is associated with treatment at high‐volume teaching facilities for patients with advanced stage laryngeal cancer , 2010, Cancer.
[24] Brian O'Sullivan,et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Roman,et al. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? , 2009, Archives of surgery.
[26] Amy Y. Chen,et al. Impact of treating facilities' volume on survival for early‐stage laryngeal cancer , 2009, Head & neck.
[27] C. Ko,et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. , 2008, Journal of the American College of Surgeons.
[28] M. Clark,et al. Ethnic/Racial Disparities in Hospital Procedure Volume for Lung Resection for Lung Cancer , 2007, Medical care.
[29] J. Birkmeyer,et al. Race and Surgical Mortality in the United States , 2006, Annals of surgery.
[30] Robert E Harbaugh,et al. Surgeon Volume and Operative Mortality in the United States. , 2004, Neurosurgery.
[31] F. Reboul,et al. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. , 2004, Hematology/oncology clinics of North America.
[32] J. Meyerhardt,et al. Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence , 2003, Annals of Internal Medicine.
[33] C. Begg,et al. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection , 2003, Journal of surgical oncology.
[34] C. Begg,et al. Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection , 2002, Annals of surgery.
[35] J. Birkmeyer,et al. Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.
[36] C. Begg,et al. The influence of hospital volume on survival after resection for lung cancer. , 2001, The New England journal of medicine.
[37] J. Birkmeyer,et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. , 1999, Surgery.
[38] E S Fisher,et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. , 1999, Surgery.
[39] C. Begg,et al. Impact of hospital volume on operative mortality for major cancer surgery. , 1998, JAMA.
[40] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[41] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[42] J. Meyerhardt,et al. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] B. Sianesi,et al. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing , 2003 .
[44] H. Wagner,et al. Treatment of stage IIIA non-small cell lung cancer. , 2003, Chest.
[45] N. Dubrawsky. Cancer statistics , 2022 .